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ABSTRACT
In 2019, the Korean Society of Maternal-Fetal Medicine developed the first Korean clinical 
practice guidelines for prenatal aneuploidy screening and diagnostic testing. These 
guidelines were developed by adapting established clinical practice guidelines in other 
countries that were searched systematically, and the guidelines aim to assist in decision 
making of healthcare providers providing prenatal care and to be used as a source for 
education and communication with pregnant women in Korea. This article delineates 
clinical practice guidelines specifically for maternal serum screening for fetal aneuploidy 
and cell-free DNA (cfDNA) screening. A total of 19 key questions (12 for maternal serum and 
7 for cfDNA screening) were defined. The main recommendations are: 1) Pregnant women 
should be informed of common fetal aneuploidy that can be detected, risks for chromosomal 
abnormality according to the maternal age, detection rate and false positive rate for common 
fetal aneuploidy with each screening test, limitations, as well as the benefits and risks 
of invasive diagnostic testing, 2) It is ideal to give counseling about prenatal aneuploidy 
screening and diagnostic testing at the first prenatal visit, and counseling is recommended 
to be given early in pregnancy, 3) All pregnant women should be informed about maternal 
serum screening regardless of their age, 4) cfDNA screening can be used for the screening of 
trisomy 21, 18, 13 and sex-chromosome aneuploidy. It is not recommended for the screening 
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of microdeletion, 5) The optimal timing of cfDNA screening is 10 weeks of gestation and 
beyond, and 6) cfDNA screening is not recommended for women with multiple gestations. 
The guideline was reviewed and approved by the Korean Academy of Medical Sciences.
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INTRODUCTION
The incidence of fetal aneuploidy increases with advancing age of women and percentage 
of advanced maternal age at or above 35 years dramatically increased from 3.8% in 1999 to 
33.3% in 2019 in Korea.1 Maternal serum screening assesses the risk of the common fetal 
aneuploidy including Down syndrome (DS) and can be performed on all pregnant women 
regardless of age. Given the low percentage of pregnant women aged 35 years or older and 
the relatively low detection rate (DR) of maternal serum screening in the past, the invasive 
diagnostic testing was recommended as a primary prenatal diagnosis of DS for women at 
or above 35 years but invasive diagnostic testing is not primarily recommended solely based 
on maternal age anymore.2,3 In Korea, the triple marker screening (“Triple” screening) was 
first introduced in 1994, and the quadruple marker screening (“Quad” screening), with 
enhanced diagnostic sensitivity for DS, was introduced in the early 2000s. Since the quad 
screening had been included in National Health Insurance coverage in 2009, it has been the 
primary maternal serum screening in the second trimester of pregnancy. With advances in 
first trimester serum screening, the combined test comprising first trimester and second 
trimester serum screening was introduced to Korea in 2006 and has enhanced DR of the DS.
Cell-free DNA (cfDNA) screening using maternal blood is also being introduced for prenatal 
screening, in addition to maternal serum screening.4 The cfDNA screening is based on the 
analysis of maternal and fetal components of cfDNA in maternal blood.5 Fetal cfDNA was 
first discovered by the genotyping of the Y chromosome detected in maternal plasma and 
serum.6 It is of placental origin but represents the entire fetal genotype. It is rapidly cleared 
from the maternal circulation within hours of delivery, making it specific for each episode of 
pregnancy.4,7,8 In the case of a fetus having DS, there will be a slight increase in the amount 
of chromosome 21-specific DNA fragments in maternal circulation. This approach forms the 
basis of cfDNA screening for aneuploidy in maternal blood, which can be performed in early 
pregnancy to reliably evaluate the DS risk and reduce the need for invasive testing such as 
chorionic villus sampling (CVS) or amniocentesis. Although the accuracy of this screening is 
dependent on the type of fetal chromosomal abnormality, it shows very high sensitivity and 
specificity for DS.9 Therefore, cfDNA screening has been widely implemented in screening 
for fetal aneuploidy during early pregnancy in many countries.10
The conventional maternal serum screening, which includes the Triple and Quad tests, is 
covered by the National Health Insurance scheme and is available to pregnant women at 
community public health service centers for free. Due to this, it has been widely performed 
on pregnant women for the detection of fetal aneuploidy.11,12 Given the differences in the 
prevalence of fetal aneuploidy, patients' preferences and country-specific clinical context,13 
a clinical practice guideline for the conventional maternal serum screening test and cfDNA 
screening is required, in order to reflect the needs of medical providers and consumers and 
to optimize the process of prenatal aneuploidy screening in Korea. There are two approaches 
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for the development of clinical practice guidelines: de novo and adaptation process. We 
chose the adaptation process for this study because of the availability of good quality practice 
guidelines for cfDNA screening developed by other countries.
METHODS
The process of guideline development
We reviewed existing guidelines and developed a Korean clinical practice guideline for maternal 
serum screening for fetal aneuploidy following the Adaptation Process for Developing Korean 
Clinical Practice Guidelines (https://www.guideline.or.kr/evaluation/sub2.php).
Forming a treatment guideline committee
To define the key questions for the clinical practice guideline, a working committee 
consisting of 12 maternal fetal medicine specialists and 1 methodology expert from 11 
medical schools and hospitals was organized by the Korean Society of Maternal Fetal 
Medicine (KSMFM). The committee was responsible for the planning, literature review, 
screening, and evaluation of the guideline development.
The process of treatment guideline development
1) Guideline search
To collect all the available forms of published clinical practice guidelines, resources including 
PubMed, EMBASE, and Cochrane Library was utilized. A literature search for prenatal 
diagnosis, fetal aneuploidy, maternal serum screening, nuchal translucency, noninvasive 
prenatal testing and cell-free DNA was conducted, with the inclusion of words such as 
‘Practice guidelines,’ ‘Guidelines,’ ‘Recommendation,’ ‘Level of evidence,’ and ‘evidence 
grade.’ We excluded the search results which lacked recommendation, were outdated as 
publications before 2008, irrelevant, or for which the full texts were unavailable. Finally, 48 
guidelines were selected for review.
2) Formulating key clinical questions
The committee initially produced 32 (19 for maternal serum and 13 for cfDNA screening) tentative 
key questions based on requirements and public opinion. The importance and urgency of the 
items were rated using a five-point Likert scale. A rating of 4 or more by > 90% of the respondents 
was regarded as necessary for the key questions, following the modified Delphi method described 
in previous studies.14 Following several rounds iterative surveys, the initial 32 items were reduced 
to the final 19 key questions (12 for maternal serum screening and 7 for cfDNA screening test). 
These questions were edited and revised for coherency and grammatical clarity.
3) Guideline assessment, selection, and adaptation
To assess the quality of selected guidelines, we used the Korean Appraisal of Guidelines for 
Research & Evaluation II (K-AGREE II) tool which is approved by the AGREE Research Trust. 
Seven existing guidelines were identified to be potentially suitable for adaptation. Based on 
the results of the K-AGREE II evaluation, we created recommendation, in accordance with 
the 19 key questions, from the selected guidelines.
4) Additional evidence searching
We further reviewed the reference papers, based on which the selected guidelines were 
developed, in order to assess the level of evidence supporting the guidelines.
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5) Guideline development and determination of the recommendation level
We wrote the guidelines and summarized evidence. Level of evidence (Table 1) and grades of 
recommendation (Table 2) were determined based on the Scottish Intercollegiate Guideline 
Network (SIGN, https://www.sign.ac.uk/assets/sign_grading_system_1999_2012.pdf ) 
translated in Korean by National Evidence-based healthcare Collaborating Agency (NECA, 
https://www.guideline.or.kr/evaluation/file/koreaguide.pdf ).
6) Consensus methodology on guideline adoption
The subcommittee members of the KSMFM, were asked to provide their level of agreement to 
each draft recommendation using a Likert scale of 1–9 (where 1 denoted strong disagreement 
and 9 denoted strong agreement) by email. We averaged each voting score and the mean 
score was used to assign the item one of three groups: 1–3 (disagreement), 4–6 (neutrality), 
and 7–9 (agreement). Based on this score, we evaluated the degree of consensus.
7) Assessment and review by external experts
External experts were invited for a public hearing during the 24th Congress of KSMFM held 
in Seoul, June 2018, and their opinions on the contents, background, and evidence of our 
guidelines were collected.
8) Approval
After several rounds of revision within the working committee, the guideline was finalized 
and approved by the Korean Academy of Medical Sciences in March 2019.
Patients for whom the guideline is applicable
The primary target population applicable is all pregnant women in Korea. The major topic is 
maternal serum screening and cfDNA test for screening of common fetal aneuploidy. The aim was 
to facilitate the establishment of Korean guidelines based on an adaptation process. The literature 
search query used took into consideration of the target population and the potential audience.
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Table 1. Levels of evidence from the ‘SIGN Grading System 1999–2012’
Levels Definition
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low-risk of bias
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low-risk of bias
1− Meta-analyses, systematic reviews, or RCTs with a high-risk of bias
2++ High quality systematic reviews of case control or cohort studies
High quality case control or cohort studies with a very low-risk of confounding or bias and a high probability that the relationship is causal
2+ Well-conducted case control or cohort studies with a low-risk of confounding or bias and a moderate probability that the relationship is 
causal
2− Case control or cohort studies with a high-risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g. case reports, case series
4 Expert opinion
SIGN = Scottish Intercollegiate Guidelines Network, RCT = randomized controlled trial.
Table 2. Grades of recommendations from the ‘SIGN Grading System 1999–2012’
Grades Definition
A At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or A body of evidence 
consisting principally of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of 
results; or Extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of 
results; or
Extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4; or Extrapolated evidence from studies rated as 2+
SIGN = Scottish Intercollegiate Guidelines Network, RCT = randomized controlled trial.
Professionals for whom guideline use is recommended
We considered that the audience of the guidelines would be healthcare providers responsible 
for the care of pregnant women. In addition, these guidelines may be used by medical students 
for learning purposes or by patients as a reference to obtain the latest medical knowledge.
Principles and method of the guideline update
The developed guidelines were listed on the website of the Korean Medical Guideline 
Information Center (‘Clinical Practice Guidelines for Prenatal Aneuploidy Screening & 
Diagnostic Tests’, https://www.guideline.or.kr/guide/view.php?number=1085&cate=A). It will 
be continuously reviewed and reevaluated for the feasibility within the national insurance 
system. The committee of the KSMFM is responsible for guideline update.
RESULTS
Key questions and recommendations
Maternal serum screening
Recommendation: Pregnant women should be informed of common fetal aneuploidy that 
can be detected, risks for chromosomal abnormality according to the maternal age, DR, and 
false-positive rate (FPR) for common fetal aneuploidy with each screening test, limitations, 
as well as the benefits and risks of invasive diagnostic testing (Level 2++, Grade A).
Summary of evidence: Chromosomal abnormality in which a chromosome is either missing 
or additionally present is known as aneuploidy. Autosomal trisomies, such as DS, are the 
most common, and their incidence rises proportionately to maternal age. While maternal 
serum screening during pregnancy can detect trisomy 21, 18, and 13, it could not screen for 
all chromosomal abnormalities. Maternal serum screening calculates the risk for aneuploidy 
by multiplying the risk for aneuploidy according to the maternal age by the likelihood ratio 
(LR) for aneuploidy based on serum screening test results. The cutoff for high-risk is 1:270, 
which is the risk for fetal DS for a woman at age 35 or above.3
Maternal serum screening is classified into first trimester screening and second trimester 
screening. The first trimester screening measures two serum biomarkers — pregnancy-
associated plasma protein A (PAPP-A) and free beta-human chorionic gonadotropin (hCG), 
and NT at 11–136/7 weeks of gestation and it has a DR for DS of 80–84% with a 5% FPR and 
positive predictive value (PPV) of 3%–4%. The second trimester screening measures four 
serum biomarkers—alpha-fetoprotein (AFP), hCG, unconjugated estriol, and inhibin A. The 
triple screening, which was first introduced in the 1990s, measures three biomarkers (AFP, 
hCG, and unconjugated estriol) in the second trimester, and its DR for DS was about 69% with 
a 5% FPR. The DR for DS was improved to 81% with a 5% FPR in the subsequently developed 
quad screening, which measures inhibin-A in addition to the previous three biomarkers.
In recent years, integrated screening test and sequential screening test, which combines the 
first trimester and second trimester maternal serum screening tests, are performed. Fully 
integrated screening test measures NT and PAPP-A between 11 and 136/7 weeks of gestation 
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•  KQ 1. What information should be given to pregnant women before performing 
maternal serum screening?
and performs quad screening test between 15 and 216/7 weeks' gestation. It has the highest 
DR for DS at 94%–96% (5% FPR) and PPV of 5%. Serum integrated screening test, which 
excludes NT, has a lower DS DR of 85%–88% compared with fully integrated test. Sequential 
test involves two types of sequential test: stepwise sequential test and contingent sequential 
test. First, maternal serum screening was examined in the first trimester to identify high-
risk women with reference to a risk cutoff of 1:30 and these high-risk women undergo 
invasive diagnostic testing in the first trimester. With the stepwise sequential test, all women 
who were not identified to be at high risk in the first trimester maternal serum screening 
undergo the quad screening in the second trimester. With the contingent sequential test, 
quad screening in the second trimester is performed only on the intermediate risk group 
(1:30–1:1,500) for DS in the first trimester maternal serum screening and omitted in the 
low- risk group (< 1:1,500). DR for DS is 92% (5.1% FPR) for the stepwise sequential test 
and 91% (4.5% FPR) for the contingent sequential test. Whereas maternal serum screening 
enables noninvasive screening of fetuses with elevated risks for trisomy 21, 18, and 13, it 
cannot detect all chromosomal abnormalities. In other words, being identified as low-risk 
in the maternal serum screening simply means that these women have a low-risk for the 
detectable chromosomal abnormalities and not that their chromosomes are all normal. 
While integrated test has the highest DR for DS among maternal serum screening tests, it 
has some limitations including not presenting the results of the first trimester screening, 
having to complete the second trimester screening, and having to undergo both blood 
samples in a same facility, which may raise issues pertaining to patient adherence. During 
the counseling for maternal serum screening for fetal aneuploidy, the healthcare providers 
must also inform women of the benefits and risks of invasive diagnostic testing. One benefit 
of invasive diagnostic testing, namely CVS and amniocentesis, is that they reveal the numeral 
and structural anomalies of all chromosomes, but they have a risk for fetal loss. The rate 
of fetal loss prior to 24 weeks' gestation due to amniocentesis between 15 and 22 weeks of 
gestation was reported to be 0.13%, and CVS in the first trimester was higher at about 1.2%. 
Counseling about the limitations of maternal serum screening should be recorded, and the 
women's decision should be fully respected. 
Recommendation: It is ideal to give counseling at the first prenatal visit, and counseling is 
recommended to be given early in pregnancy (Level 2++, Grade A).
Summary of evidence: Women should be given sufficient time to understand the information 
about fetal aneuploidy screening and invasive diagnostic testing offered during counseling 
and make their own informed decision. In the first trimester, serum screening would 
be performed in addition to NT measurement at 11–136/7 weeks, and it would be ideal to 
give counseling about fetal aneuploidy screening and invasive diagnostic testing before 
the antenatal visit for NT measurement, so that fetal aneuploidy screening could be 
performed at the appropriate timing and women can make their own choices. It has been 
reported that 96.8% of women who receive prenatal care within the first trimester choose 
integrated screening, which has the highest DR for DS among maternal serum screening 
tests. American College of Obstetrics & Gynecology recommends offering fetal aneuploidy 
screening and invasive diagnostic testing on the first prenatal visit, because women have 
fewer prenatal visits overall due to differences in access to healthcare and insurance 
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•  KQ 2. When should counseling about maternal serum screening or invasive diagnostic 
testing be given?
systems.15 However, considering the high frequency of miscarriage in early pregnancy, the 
National Health Insurance system, and relatively high access to healthcare in Korea, it would 
be more appropriate to set the timing of counseling as any time before the NT measurement 
in the first trimester instead of at the first prenatal visit.
Recommendation: All pregnant women should be informed about maternal serum screening 
regardless of their age (Level 2++, Grade A).
Summary of evidence: As the incidence of fetal aneuploidy increases with increased 
maternal age, advanced maternal age at 35 years or older itself was considered an indication 
for invasive prenatal testing in the past.3 Since then, maternal age continued to rise and 
advances of first trimester maternal serum screening and NT have enhanced the accuracy of 
maternal serum screening. These days, because Korea features a high percentage of advanced 
maternal age at 35 years or older, at 33.3% in 2019, one in every three women must undergo 
amniocentesis if amniocentesis were to be recommended to all pregnant women aged 35 
years or older. According to Resta et al. the percentage of advanced maternal age at or above 
35 years rose from 4.57% in 1980 to 14% in 2002. If amniocentesis would be recommended 
for all pregnant women aged 35 years or older, it detects 51% of DS with 13.77% FPR, showing 
an inferior screening power compared to the maternal serum screening at the time. With 
improved accuracy of maternal serum screening and increased advanced maternal age, 
assessing the risk for DS with maternal serum screening is superior to assessing it based on 
maternal age, and for this reason, invasive diagnostic testing is not primarily recommended 
solely based on maternal age.
The risk for fetal aneuploidy in twin pregnancy differs not only by maternal age but also by 
zygosity. Dizygotic twins are at an elevated risk for fetal DS compared to single fetuses of 
women at the same maternal age, and thus the risk for aneuploidy is comparable between 
twin pregnancy aged 32 years or older and singleton pregnancy aged 35 years older. In recent 
years, the increased use of assisted reproduction techniques (ARTs) have led to an increase 
in twin pregnancies, and the incidence of both dizygotic twins and monozygotic twins have 
risen. Zygosity may be diagnosed based on the use of ART or chorionicity, but chorionicity 
alone is not sufficient to accurately determine zygosity, as 33% of monozygotic twins are 
dichorionic. Moreover, because the risk of fetal loss due to invasive diagnostic testing was 
known to be higher for twins than for singletons, assessing fetal risk for DS using maternal 
serum screening is recommended over using maternal age alone in twin pregnancies as well. 
Performing invasive diagnostic testing without screening should be limited to cases involving 
intrauterine fetal death or structural abnormality of one fetus.
Recommendation: If maternal serum screening results are low-risk, performing additional 
independent serum screening is not recommended, as it may increase false positive result 
(Level 2++, Grade A).
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•  KQ 3. Does counseling for maternal serum screening differ by the age of the woman?
•  KQ 4. If maternal serum screening results are low-risk, is it appropriate to perform 
additional serum screening?
Summary of evidence: Performing first trimester and second trimester serum screening 
independently of one another without using them as a part of combined test increases FPR 
without increasing the DR for fetal aneuploidy. Because the quad screening has a lower 
DR for fetal aneuploidy with higher FPR compared to the first trimester maternal serum 
screening including NT, first trimester screening is superior to the quad screening when 
performed independently. Therefore, both healthcare providers and pregnant women must 
be aware of the fact that the risk for FPR may increase without better DR for fetal aneuploidy 
if a woman who was low-risk in the first trimester maternal serum screening undergoes the 
quad screening in the second trimester at a different facility.
Recommendation: Healthcare providers should explain that the result indicating high-risk 
does not confirm fetal abnormality and offer counseling about cfDNA screening or invasive 
diagnostic testing (Level 2++, Grade A).
Summary of evidence: In the maternal serum screening, the individual risks for trisomy 21 
and 18 are analyzed, and the woman is classified as high-risk if a certain threshold of risk 
is met. It should be explained to the woman that the result indicating high-risk does not 
confirm fetal abnormality and that it is an outcome of a combined analysis of the existing 
risk for fetal aneuploidy according to maternal age and the serum test results. Further, after 
informing the woman of the accuracy of each serum screening test and confirming that they 
have understood the test results, healthcare providers should explain the pros and cons of 
further tests to be considered in detail.
Healthcare providers should first recommend invasive diagnostic testing to high-risk women 
and explain the method, safety, and cost. Women should be informed that CVS could be 
performed prior to 14 weeks' gestation and amniocentesis could be performed after 14 weeks' 
gestation and should undergo testing accordingly. CVS can detect chromosomal abnormality 
at a rate of 98%–99%, with < 1% mosaicism, < 1% risk of maternal cell contamination, 
and 0.5%–1.2% procedure-related fetal loss rate. The accuracy of genetic amniocentesis 
performed in the second and third trimesters was reported as 99.8%–99.9%, and while the 
procedure-related fetal loss rate was 1/200, that is, 0.5%, but recent reports showed lower 
fetal loss rate at 0.06%–0.13%. Amniocentesis is not recommended in the first trimester due 
to increased risk of amniotic fluid leakage and equinovarus.16
While fetal chromosomal abnormality can be diagnosed only based on invasive diagnostic 
testing, some women prefer noninvasive ‘blood’ test as an alternative due to concerns about 
fetal safety from invasive testing. Maternal serum screening should not be performed again in 
these women, as doing so would be not cost-effective. The cfDNA screening detects trisomy 
21, 18, and 13 at a high DR with low FPR by analyzing the amount of fetal DNA circulating 
in maternal plasma and thus can be a reasonable alternative for women who prefer a 
noninvasive test. The cfDNA screening has been showing a highest sensitivity of 99.3% and 
specificity of 99.8% for trisomy 21, 97.4% and 99.8% for trisomy 18. The sensitivity is 91% 
and specificity is > 99% for trisomy 13 and monosomy X.17,18 However, the risk for fetal 
chromosomal abnormality other than common autosomal trisomies was reported to be 2% 
in cases with high-risk in the traditional maternal serum screening and low-risk in the cfDNA 
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•  KQ 5. Which tests and counseling should be given to women identified as high-risk in 
the maternal serum screening?
screening. Also, women should be well informed that the cfDNA screening could delay the 
diagnosis for fetal chromosomal abnormality in true positive cases because women with 
high-risk in the cfDNA screening must be taken invasive diagnostic testing. Women should 
be well informed that cfDNA screening is not a diagnostic test.
Recommendation: Clinical information such as gestational age, maternal body weight, race, 
insulin-dependent diabetes mellitus, number of fetuses, and ultrasonographic fetal size 
should be provided to the laboratory (Level 2++, Grade A).
Summary of evidence: Various clinical factors are involved in the analysis of the results of 
maternal serum screening. Thus, this clinical information must be accurately recorded 
and included in the analysis in order to obtain accurate results. The concentrations of each 
serum biomarkers are converted to multiples of median (MoM) according to gestational 
age. Calculating the gestational age based on ultrasonographic measurement has been 
reported to lower the FPR by about 2%. With increasing maternal body weight, blood volume 
increases and dilutes the concentration of maternal serum biomarkers, thereby reducing 
the concentration of maternal serum factors. Adjusting for maternal body weight during 
the second trimester screening could increase the DR by 1% with a fixed FPR or reduce 
the FPR by about 0.2% with a fixed DR. The mean values of serum biomarkers vary across 
ethnicities. Compared to Caucasian women, South Asian women have 6% lower AFP, 7% 
higher unconjugated estriol, 6% higher hCG, and 17% higher PAPP-A, and black women have 
15% higher AFP, 18% lower hCG, 8% higher inhibin A, and 35% higher PAPP-A. Therefore, 
adjusting for racial differences may enhance the DR at a fixed FPR. The concentrations of 
two second trimester serum biomarkers—AFP and unconjugated estriol—are 10% and 5% 
lower, respectively, in insulin-dependent diabetes mellitus, while the concentrations of other 
biomarkers do not vary in relation to diabetes mellitus. Women who conceived with ART 
show high second trimester free beta-hCG and total hCG, and studies have reported that 
the FPR may increase by two times in these women. While Wald et al. proposed that high 
FPR could be avoided by adjusting for the use of ART,19 recent studies stated that adjusting 
for ART does not improve the FPR. First trimester PAPP-A concentration is low in ART 
pregnancies, but hCG results are inconsistent.
Recommendation: For women who underwent the first trimester screening, maternal serum 
AFP is recommended for screening of NTD in the second trimester and then ultrasonography 
is recommended for detection of other structural abnormality. For women above 20 weeks' 
gestation, ultrasonography should be performed for screening of NTD (Level 2++, Grade A).
Summary of evidence: NTD screening should be recommended to all pregnant women 
regardless of age. MSAFP can be performed between 15 and 216/7 weeks of gestation, 
desirably between 16 and 18 weeks for NTD screening, and analysis is difficult prior to 15 
weeks. Because the risk for NTD cannot be predicted with the first trimester maternal serum 
9/19https://jkms.org https://doi.org/10.3346/jkms.2021.36.e27
Clinical Practice Guidelines for Prenatal Aneuploidy Screening
•  KQ 6. What clinical information can influence the accuracy of analysis in maternal 
serum screening?
•  KQ 7. How should fetal neural tube defect (NTD) or other structural anomalies be 
screened in women who underwent serum screening in the first trimester?
screening or cell-free DNA screening, MSAFP must be performed in the second trimester in 
such cases. NTD is a different congenital abnormality from fetal aneuploidy, so healthcare 
providers should give information about MSAFP screening to women prior to 216/7 weeks 
of gestation even if they decided not to undergo the fetal aneuploidy screening. If MSAFP 
screening is chosen, the results must be analyzed after adjusting for ultrasound-based 
gestation age, body weight, insulin-dependent diabetes mellitus, race, and a number of 
fetuses. Using a cutoff of 2.5 MoM for MSAFP in the second trimester, 73%–83% of open 
NTD was diagnosed.
Recommendation: Invasive diagnostic testing for fetal chromosomal abnormality and 
detailed ultrasonography to examine structural anomalies should be performed (Level 2++, 
Grade A).
Summary of evidence: NT can be measured between 11 and 136/7 weeks of gestation, with 
the highest accuracy between 11 and 12 weeks. Chromosomal abnormality was found in 35% 
of cases with NT between 3–8 mm, and various structural abnormalities were associated 
although fetal karyotype was normal. NT increases by 15%–20% depending on gestational 
age, so recent DS screening programs calculate the risk by converting the values into MoM for 
the specific gestational age. According to a single center study about gestational age and NT 
thickness in Korea by Chung et al. in 2004, the ethnic difference was not significant, and as 
no past studies have reported a racial difference in NT, it would be acceptable to directly apply 
foreign criteria. If NT is ≥ 99th percentile or 3 mm or greater between 11 and 136/7 weeks of 
gestation regardless of gestational age, the likelihood of aneuploidy is high at 1:6, and even if 
combined with maternal serum screening, only 8% of these cases have the risk for DS lowered 
to 1:200. Most of these cases still are at high-risk and need to consider invasive diagnostic 
testing, based on which it would be appropriate to recommend invasive prenatal testing 
without serum screening. Moreover, enlarged NT to 3 mm or higher was only observed in 
0.5% of the cases, so the overall medical cost would not increase much. An enlarged NT (≥ 3.0 
mm) can detect fetal DS with a 69%–75% DR with 5.0%–8.1% FPR. Regarding cystic hygroma, 
51% of the cases are accompanied by chromosomal abnormality, and 34% with normal 
karyotype are accompanied by major heart and skeletal anomalies. Therefore, when cystic 
hygroma is observed, clinicians should recommend invasive diagnostic testing and perform 
detailed ultrasonography to identify other structural anomalies.
Recommendation: Detailed ultrasonography for structural abnormality and fetal 
echocardiography should be performed in the second trimester and women should be 
informed of the possibility of genetic syndrome undetected through fetal karyotyping and 
increased risk for poor perinatal outcomes (Level 2++, Grade A).
Summary of evidence: Enlarged fetal NT is also associated with the genetic syndrome 
and fetal structural anomalies such as heart, abdominal wall, and musculoskeletal system 
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•  KQ 8. What tests should be performed on women with enlarged NT, obvious structural 
abnormality and cystic hygroma in the first trimester ultrasound?
•  KQ 9. What is the protocol for follow-up and additional tests in cases in which enlarged 
fetal NT or cystic hygroma with normal karyotype?
in addition to fetal chromosomal abnormality. Survival rate decreases with increasing NT 
thickness, where survival rate decreases from 96.3% when NT < 3.5 mm to 44.4% when 
NT ≥ 6.5 mm, and the incidence of fetal abnormality and genetic syndrome also increase 
with increasing NT thickness. The incidence of cystic hygroma was reported to be 1/285 
first-trimester pregnancies and of them, 51% have chromosome abnormality. Among cystic 
hygroma with normal karyotype, 34% had fetal structural abnormality and intrauterine death 
occurred in 8% of normal karyotype, and 4% of survivors were reported to have cerebral palsy 
and developmental disorder. Cystic hygroma has poorer prognosis compared to a simple 
enlargement of NT, where the risks for fetal aneuploidy, heart anomaly, and perinatal death are 
5 times, 12 times, and 6 times higher, respectively. Therefore, if normal karyotype is confirmed 
in a fetus with enlarged NT or cystic hygroma in the first trimester, a detailed ultrasonography 
and fetal echocardiography should be performed in the second trimester to examine for 
structural anomalies. Clinicians should inform women with enlarged NT or cystic hygroma of 
the risk for undiagnosed genetic syndrome and risk for poor perinatal outcomes.
Recommendation: In cases with an isolated minor marker related to aneuploidy in the 
second trimester ultrasound, prenatal aneuploidy screening is recommended if it was not 
performed. If fetal aneuploidy screening was performed in the first or second trimester and 
the result was low-risk, an additional test is not recommended (Level 2++, Grade B).
Summary of evidence: Ultrasonographic minor markers are generally normal variants 
identified on second trimester but can be associated with fetal DS (Table 3).20,21 They are 
relatively common enough to be found in 10% of normal pregnancies and do not mean 
fetal abnormalities or affect prognosis in absence of fetal aneuploidy. Because the LR of 
DS differs for each minor marker, each minor marker should be assessed in consideration 
of the woman's overall clinical situation. According to Nyberg et al.,21 an analysis of the 
LR of nuchal fold thickening, echogenic bowel, short femur, echogenic intracardiac focus, 
and renal pelvis dilation for DS revealed that nuchal fold thickening had the highest LR (LR 
11), followed by echogenic bowel (LR 6.7), with the remaining minor markers having a LR 
of 1.0–2.0. Other studies have identified nuchal fold thickening as the minor marker with 
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•  KQ 10. What tests should be performed if an isolated ultrasonographic minor marker 
related to DS is detected alone in the second trimester?
Table 3. Minor markers associated with fetal Down syndrome on second trimester
Ultrasonographic markers
Aberrant right subclavian artery
Brachycephaly or shortened frontal lobe




Nasal bone absence or hypoplasia
Nuchal fold thickening
Renal pelvis dilation (mild)






the strongest association with DS, highlighting the need for detailed ultrasonography and 
counseling to evaluate for the presence of other minor markers in cases showing nuchal fold 
thickening in the second trimester ultrasound. One study reported that echogenic bowel 
could result from swallowing blood in the amniotic fluid and that it does not increase the 
risk for DS. Echogenic intracardiac focus is reported to occur in up to 30% of Asian pregnant 
women, which should be taken into consideration when applying it as a minor marker in 
Korean women. While nasal bone hypoplasia improves DR of DS when combined with other 
minor markers, additional test is not recommended solely based on nasal bone hypoplasia. 
Thus, if minor markers other than nuchal fold thickening are detected alone, it is desirable to 
perform fetal aneuploidy screening if it had not been previously performed and an additional 
test is not recommended if the fetal aneuploidy screening result was low-risk. When 
adjusting for the risk of existing maternal serum screening using minor markers, the relative 
LRs of positive and negative findings should be applied systematically, and if the marker is 
present alone, it has little impact on the existing maternal screening test. In particular, if 
cfDNA screening was already performed and its result was low-risk, the detection of a single 
minor marker does not warrant additional test or risk readjustment. Choroid plexus cyst was 
excluded from the list of minor markers of DS.
Recommendation: Pregnant women should be informed that maternal serum screening tests 
have lower accuracy in twin pregnancies than in singleton pregnancies (Level 2++, Grade B).
Summary of evidence: The risk for fetal aneuploidy in twin pregnancy is affected by the 
number of fetuses and zygosity. When assessed according to maternal age, the risk for fetal 
DS is equal between monozygotic twin pregnancy and singleton pregnancy but increases in 
dizygotic twin pregnancy, as each of the dizygotic twin has a risk for fetal aneuploidy. However, 
data on maternal serum screening is relatively lacking for twin pregnancies compared to 
singleton pregnancies, and as maternal serum screening assesses the overall risk present in 
pregnancy as opposed to assessing the risk for each fetus, it has a lower accuracy for twin 
pregnancies compared to singleton pregnancies. According to the cohort study by Neveux et 
al.,22 the DR for fetal DS with triple screening is 73% in monozygotic twin pregnancy, 43% 
in dizygotic twin pregnancy, and 53% overall with 5% FPR, which were lower than that in 
singleton pregnancy. According to Wald et al.'s study,23 integrated test detected DS in 93% in 
monochorionic twins, 78% in dichorionic twins, and 80% in all twin pregnancies with 5% FPR, 
but the results were not confirmed with a prospective study. Based on the fact that integrated 
test that combines NT and maternal serum screening enhances the DR while lowering the FPR 
in singleton pregnancies, the same strategy is currently used for twin pregnancies; however, 
this method has not been prospectively validated, so pre- and post-test counseling is essential 
when performing maternal serum screening in twin pregnancy.
Recommendation: Maternal serum screening is not recommended when fetal demise or 
major structural abnormality is identified in one fetus in twin pregnancies. In such cases, 
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•  KQ 11. Can maternal serum screening be recommended in twin pregnancies with an 
equal accuracy with that in singleton pregnancies?
•  KQ 12. Is maternal serum screening appropriate when fetal demise or major structural 
abnormality is identified in one fetus in twin pregnancies?
invasive diagnostic testing can be considered to diagnose for fetal chromosomal abnormality 
(Level 2++, Grade B).
Summary of evidence: Multifetal pregnancy is associated with a higher incidence of 
miscarriage and fetal anomaly compared to a singleton pregnancy, and there are cases in 
which one fetus dies in utero or has structural abnormalities while the co-twin is normal. 
Vanishing twin, which refers to the loss of one embryo early in pregnancy, occurs in 10%–
40% of all twin pregnancies, and this can impact the concentration of serum biomarkers 
even after a prolonged period. Concentrations of serum biomarkers were compared between 
vanishing twin and singleton pregnancy in consideration of same gestational age and 
maternal age, and the results showed that the vanishing twin group had 21% higher PAPP-A 
in the first trimester and 10% higher AFP and 13% higher inhibin A in the second trimester. 
The concentrations of PAPP-A and AFP levels showed a negative correlation with time interval 
between the occurrence of fetal demise and blood sampling, so PAPP-A value was similar 
to that of singleton pregnancy after 4 weeks, but it was found that the concentrations of 
hCG and inhibin A did not change over time. Therefore, maternal serum screening would 
lead confusion with its results in cases involving a vanishing twin and is not recommended. 
Similar to the consideration of invasive diagnostic testing in a singleton pregnancy with 
structural abnormality, it is appropriate to consider invasive diagnostic testing in twin 
pregnancies involving one fetus with structural abnormality.
Cell-free DNA screening
Recommendation: All pregnant women can be informed and offered the choice of cfDNA 
screening, although the first priority for these tests should be the high-risk group (Level 2++, 
Grade B).
Summary of evidence: The cfDNA screening shows similar sensitivity and specificity in 
both low and high-risk groups.24-28 Given the low PPV of this test in low-risk group and 
the possibility of ‘no call’ from inadequate sample, in terms of cost-effectiveness, it is not 
recommended for all pregnant women.
Recommendation: cfDNA screening can be used for the screening of trisomy 21, 18, 13 and 
sex-chromosome aneuploidy. It is not recommended for the screening of microdeletion 
(Level 2++, Grade B).
Summary of evidence: The cfDNA screening demonstrates high reliability in detecting 
trisomy 21, 18, and 13. While this method shows the highest sensitivity (99.3%) and 
specificity (99.8%) for trisomy 21, the sensitivity is 97.4% and specificity is 99.8% for trisomy 
18. The sensitivity is 91% and specificity is > 99% for trisomy 13 and monosomy X. In the 
high-risk group, aged 40 or older, PPV is 87%, 68%, and 57% for trisomy 21, 18, and 13, 
respectively.17,18,29-31 The false positive rate of cfDNA screening for common trisomy is 1%, 
and even < 1% for trisomy 21. The performance of this screening may be affected by placental 
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•  KQ 1. Who should be offered the option of cfDNA screening?
•  KQ 2. What types of chromosomal abnormalities can be screened with cfDNA 
screening?
mosaicism, vanishing twin, maternal copy number variations and maternal malignant tumor. 
The DR for monosomy X is over 90% and false positive rate is 1%.18,32-34 In a study using 
prospectively collected samples, PPV for monosomy X was 48.4% (30%–67%).18 It should be 
conveyed that there can be a false positive result for sex chromosome abnormality, which may 
have varied clinical implication in the presence of maternal sex chromosome mosaicism.35 
The cfDNA screening for microdeletions is not recommended because the PPV ranges from 
3.8 to 17%, which precludes practical implication.36
Recommendation: 1) It should be clarified that a ‘low-risk’ result does not mean the absence 
of chromosomal abnormality. 2) A mother with a result of ‘no call’ should be offered the 
invasive test, rather than a retest (Level 2++, Grade B).
Summary of evidence: Although it shows good performance in the screening of trisomy 21, 
18, and 13, several studies have reported false positive and false negative cases.37,38 Therefore, 
confirmative diagnosis should be made only after the invasive test has been performed. 
Likewise, women with a negative result should be informed that it does not rule out all 
abnormalities in fetal chromosomes.39 In cases of a failure to obtain result (‘no call’), the 
woman is more likely to have fetal aneuploidy such as trisomy 18 and 13.28,40 The success rate 
of the repeat test is reported to be as low as 45%–50% or as high as 80%–90%, depending 
on the study setting.41 Considering the higher risk of abnormal result and the anxiety of 
women who have to wait for the test to be repeated, we do not recommend repeating cfDNA 
screening in women with ‘no call’ result. This ‘no call’ result is more common in women 
with obesity, with the prevalence being 20% when the bodyweight is > 113 kg (250 lb) and 
50% when it is > 159 kg (350 lb).42 Thus, cfDNA screening would not be the optimal fetal 
aneuploidy screening test in pregnancy for women with severe obesity.43
Recommendation: The cfDNA screening cannot be offered as a first-line aneuploidy 
screening test for all women because it is not cost-effective in low-risk pregnancy (Level 2++, 
Grade B).
Summary of evidence: On an average, cfDNA screening shows better performance in 
detecting chromosomal trisomy compared to the conventional maternal serum screening 
test.40 However, PPV of cfDNA screening is lower in the low-risk group compared to the 
high-risk group. There is also the possibility of ‘no call,’ when the amount of placenta-derived 
cell-free DNA in maternal blood is not sufficient for the test. Comparing to the analyte-
based tests, which are frequently positive for a large range of chromosomal abnormalities, 
cfDNA screening is specific for individual aneuploidies.44 Of abnormal result from invasive 
diagnostic testing, 16.9% of all abnormalities detected by invasive diagnostic testing were 
considered undetectable by the current cfDNA screening.45 Given the high cost of cfDNA 
screening, it is not cost-effective to recommend this test for all pregnant women.
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•  KQ 3. What should be addressed in the counseling following cfDNA screening?
•  KQ 4. Is cfDNA screening superior to maternal serum screening for fetal aneuploidy 
screening?
Recommendation: The optimal timing for cfDNA screening is 10 weeks of gestation and 
beyond (Level 2++, Grade A).
Summary of evidence: The proportion of fetal component in cfDNA in maternal blood has 
been known to remain constant between gestational weeks 10 and 22, regardless of maternal 
ethnicity or age.46 Recently, some reports have shown that the proportion of fetal component 
is closely associated with gestational age; fetal component in cfDNA increases by 0.1% per 
week during gestational weeks 10–21 and by 1% after gestational week 21.47,48 For most 
pregnant women, the proportion of fetal component is > 4% after gestational week 10, which 
is sufficient for cfDNA screening. The test is likely to fail to yield a result before gestational 
week 9, with only 72.6% success rate.28 Therefore, it is recommended that cfDNA screening 
be performed after gestational week 10.
Recommendation: Cell-free DNA screening is not recommended for women with multiple 
gestations, since the accuracy in multiple pregnancy is not as high as that in singleton 
pregnancy (Level 1+, Grade B).
Summary of evidence: Twin pregnancy generally shows lower fetal component in cfDNA of 
maternal blood than singleton pregnancy (7.4% vs. 10% or 8.7% vs. 11.7%).49,50 The failure 
rate was also shown to be higher in twin pregnancy.50,51 Therefore, cfDNA screening is not 
recommended in twin pregnancy because of poorer performance compared to a singleton 
pregnancy.
Recommendation: Women with a high-risk result should be offered the option of having 
an invasive test. It should be urged that no irreversible obstetric procedures be undertaken 
without a confirmative diagnostic test (Level 2++, Grade B).
Summary of evidence: Given the false positive and false negative cases and the varied 
accuracy, depending on the type of aneuploidy, cfDNA screening should not be regarded 
as a confirmative test.37-40,52 According to a study of 31,030 women, the PPV for all types of 
trisomy was 82.9% and for trisomy 21 it was 90.9%.53 Therefore, drawing conclusions of fetal 
aneuploidy, based on a high-risk result without any invasive testing, should be avoided.
15/19https://jkms.org https://doi.org/10.3346/jkms.2021.36.e27
Clinical Practice Guidelines for Prenatal Aneuploidy Screening
•  KQ 5. When can cfDNA screening be performed during pregnancy? Is there an optimal 
timing for cfDNA screening?
•  KQ 6. Is the result of cfDNA screening also valid in multiple pregnancy, as it is in 
singleton pregnancy?
•  KQ 7. What are the recommendations for women whose result is high-risk in cfDNA 
screening?
SUMMARY
Our guidelines aim to define an optimal application of maternal serum screening and cfDNA 
test as a fetal aneuploidy screening test; however, the ultimate decision should be made by 
the women and physicians. The purpose of this guideline is to reduce an unnecessary invasive 
test and the misinformation on the termination of pregnancy. This guideline provides 
evidence for a cost-effective strategy for prenatal aneuploidy testing and a reference for 
reimbursement by the national health insurance. Based on this guideline, we will be able to 
establish more effective prenatal care system and programs to improve maternal fetal health, 
as well as a research basis of maternal fetal medicine.
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